Antibody-drug conjugates (ADCs) Products

Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of patients with cancers. Typically, an ADC is composed of three core elements: the monoclonal antibody, the linker and the cytotoxic agent. In developing ADCs, an anticancer drug is coupled to an antibody that specifically targets a certain tumor marker (e.g. a protein that, ideally, is only to be found in or on tumor cells). Antibodies track these proteins down in the body and attach themselves to the surface of cancer cells. The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then absorbs or internalizes the antibody together with the cytotoxin. After the ADC is internalized, the cytotoxic drug is released and kills the cancer.Typical examples areBrentuximab vedotin (SGN35), Trastuzumab-emtansine (T-DM1), Inotuzumab ozogamicin (CMC-544) and Gemtuzumab ozogamicin.

Creative Biolabs scientists are focusingon applying excellent science and technology to discover and develop potential new ADCs with the goal of becoming first-in-class therapeutics. We also provide custom ADCsdesign and construction services. Besides expression and purification of ADCs, we also provided pharmacokinetics studies, HPLC/ELISA/TFC-MS/MS analysis for free drug and pharmacokinetics analysis.

 

 

ADC Name

Cytotoxin

Linker

MAb

Target

ABT-414-VC-MMAE

Auristatin MMAE

Valine–citrulline

ABT-414

EGFR

AGS-16M8F-VC-MMAE

Auristatin MMAF

Valine–citrulline

AGS-16M8F

AGS-16

AMG-172-SMCC-DM1

Maytansine DM1

SMCC

AMG-172

CD70 (CD27L)

AMG-595-SMCC-DM1

Maytansine DM1

SMCC

AMG-595

EGFRviii

ARX788

Amberstatin (AS269)

Valine–citrulline

ARX788

HER2

ASG-15ME-VC-MMAE

Auristatin MMAE

Valine–citrulline

ASG-15ME

SLTRK6

ASG-22CE-VC-MMAE

Auristatin MMAE

Valine–citrulline

ASG-22CE

Nectin 4

ASG-22ME-VC-MMAE

Auristatin MMAE

Valine–citrulline

ASG-22ME

Nectin 4

ASG-5ME-VC-MMAE

Auristatin MMAE

Valine–citrulline

ASG-5ME

SLC44A4 (AGS-5)

BAY-79-4620-VC-MMAE

Auristatin MMAE

Valine–citrulline

BAY-79-4620

CA-IX

BAY-94-9343-SPDB-DM4

Maytansine DM4

SPDB

BAY-94-9343

Mesothelin

BIIB015-MCC-MMAE

Auristatin MMAE

MCC

BIIB015

CFC1B (Cripto)

Brentuximab-VC-MMAE

Auristatin MMAE

Valine-citrulline

Brentuximab vedotin (SGN35)

CD30

BT-062-SPP-DM4

Maytansine DM4

SPP

BT-062

CD138

Coltuximab-SPDB-DM4

Maytansine DM4

SPDB

Coltuximab Ravtansine (SAR-3419)

CD19

EC-mAb-Maleimidocaproyl Phenylalanine-PBD dimer

Pyrrolobenzodiazepine (PBD) dimer

Maleimidocaproyl Phenylalanine

SGN- CD33A (EC-mAb)

CD22

Epratuzumab–Lysine-SN38

Irinotecan metabolite (SN38)

Lysine

Epratuzumab–SN-38

CD33 and CD22

Gemtuzumab-Hydrazone-N-acetyl- γ Calicheamicin

N-acetyl- γ Calicheamicin

Hydrazone

Gemtuzumab ozogamicin

GPNMB (Glycoprotein NMB)

Glembatumumab-VC-MMAE

Auristatin MMAE

Valine–citrulline

Glembatumumab vedotin (CDX-011)

Tissue Factor (TF)

HuMax-TF-VC-MMAE

Auristatin MMAE

Valine–citrulline

HuMax-TF-ADC

CD37

IMGN-529-SPDB-DM4

Maytansine DM4

SPDB

IMGN-529

Folate receptor 1

IMGN-853-Lysine-SN38

Irinotecan metabolite (SN38)

Lysine

IMGN-853

TACSTD2 / TROP2 or EGP1

IMMU-132-Hydrazone-Doxorubicin

Doxorubicin

Hydrazone

IMMU-132 (hRS7-SN38)

CD22

Inotuzumab-Hydrazone-N-acetyl- γ Calicheamicin

N-acetyl- γ Calicheamicin

Hydrazone (4-(4-acetylphenoxy)butanoic acid)

Inotuzumab ozogamicin (CMC-544)

CEA-CAM4/CD66e

Labetuzumab-Carbonate-SN38

Irinotecan metabolite (SN38)

Carbonate

Labetuzumab-SN-38 (IMMU-130)

CD56

Lorvotuzumab-N-succinimidyl-4-(2-pyridyldithio)butyrate-DM1

Maytansine DM1

(N-succinimidyl-4-(2-pyridyldithio)butyrate)

Lorvotuzumab mertansine (IMGN-901)

CD70 (TNFSF7)

MDX-1203-Di-peptide-Duocarmycin

Duocarmycin (DNA damage)

Di-peptide

MDX-1203

STEAP1

Milatuzumab doxorubicin (IMMU-110)

Doxorubicin

Hydrazone

Milatuzumab doxorubicin (IMMU-110)

Mucin 16

MLN-0264-VC-MMAE

Auristatin MMAE

Valine–citrulline

MLN-0264

CD79b

PF-0626350-VC-MMAE

Auristatin MMAE

Valine–citrulline

PF-0626350

Pinatuzumab-VC-MMAE

Auristatin MMAE

Valine–citrulline

Pinatuzumab vedotin (RG-7593 / DCDT 2980S)

NaPi2b

PSMA-ADC-SPDB-DM4

Maytansine DM4

SPDB

PSMA-ADC

RG-7450-VC-MMAE

Auristatin MMAE

Valine–citrulline

RG-7450 / DSTP 3086 S

Endothelin receptor ETB

RG-7458-SMCC-DM1

Maytansine DM1

SMCC

RG-7458 / DMUC 5754 A

CA6

RG-7596-VC-MMAE

Auristatin MMAE

Valine–citrulline

RG-7596 / DCDS4501A

RG-7599-VC-MMAE

Auristatin MMAE

Valine–citrulline

RG-7599 / DNIB 0600 A

CD70

RG-7600-VC-MMAE

Auristatin MMAE

Valine–citrulline

RG-7600

CD70

RG-7636-VC-MMAE

Auristatin MMAE

Valine–citrulline

RG-7636

CD19

SAR-566658-SPDB-DM4

Maytansine DM4

SPDB

SAR-566658

LIV1

SC16LD6.5-Di-peptide-DNA damaging agent

DNA damaging agent

Di-peptide

SC16LD6.5

HER2

SGN-75-VC-MMAE

Auristatin MMAF

Valine–citrulline

SGN-75

CD70

SGN-CD19A-VC-MMAE

Auristatin MMAE

Valine–citrulline

SGN-CD19A

SGN-LIV1-A-VC-MMAE

Auristatin MMAE

Valine–citrulline

SGN-LIV1-A

SGN-Maleimidocaproyl Phenylalanine-PBD dimer

Pyrrolobenzodiazepine (PBD) dimer

Maleimidocaproyl Phenylalanine

SGN CD70 A

Trastuzumab-SMCC-DM1

Maytansine DM1

SMCC

Trastuzumab-emtansine (T-DM1)

Vorsetuzumab-VC-MMAE

Auristatin MMAF

Valine–citrulline

Vorsetuzumab mafodotin

 

                                                return

 

株式会社 バイオロジカ
名古屋市中区大須4-10-40
 biologic@rr.iij4u.or.jp
 052-262-6732